



BML

Anti-human PAF-AH Antibody PAF-AH A7G

ORDERING INFORMATION

Catalog Number: BML020

Lot Number:

Size: 50 µg

Formulation: 0.2 µm filtered PBS solution

Storage: -80°C

Specificity: human plasma PAF-AH

Immunogen: PAF-AH purified from pooled plasma

Ig Type: IgG1

Application: Western blot

Sandwich ELISA

Preparation

Produced in mice immunized with platelet-activating factor acetylhydrolase (PAF-AH) purified from human plasma. PAF-AH specific IgG was purified from mouse ascites fluid with a protein A-Sepharose.

Formulation

0.2 µm filtered PBS solution

Storage

IgG in PBS solution are stable for twelve months from the date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles.

Specificity

This antibody has been selected for its ability to bind for human PAF-AH (1).

Additional Applications

Western Blot – This antibody can be used at 0.5 – 1.0 µg/mL with the appropriate secondary reagent to detect human plasma PAF-AH. The detection limit for purified PAF-AH and plasma sample is approximately 0.01 µg/lane and 0.05 µL/lane, respectively, under non-reducing and reducing conditions.

Sandwich ELISA – The biotinylated antibody (Catalog #BML021) can be used as a detection antibody in a human plasma PAF-AH ELISA in combination with the monoclonal capture antibody (Catalog #BML019). The detail for ELISA protocol is described in the reference 1. Using plates coated with 100 µL/well of the capture antibody, in combination with 100 µL/well of the detection antibody at 0.5 µg/mL, an ELISA for sample volumes of 100 µL can be obtained. Titrate each preparation of the serum sample for standard preparation to arrive at the most suitable dose range. For this antibody pair, a two-fold dilution series starting at 80 ng/mL is suggested. For more information, please see the reference (1).

Optimal dilutions should be determined by each laboratory for each application.

References

- (1) Kujiraoka et al., Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes. *J Lipid Res*, 2003;44:2006-2014.
- (2) Ishihara et al., Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. *J Hum Genet*, 2004;49:301-307.
- (3) Kujiraoka et al., Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid. *Atherosclerosis*, 2004;176:57-62.

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

BML, Inc.

1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan

TEL +81-49-232-0440/FAX +81-49-232-5480